Ultimovacs: A Universal Cancer Vaccine - Redeye

Redeye initiates coverage of Ultimovacs, a Nordic biotech company developing therapeutic cancer vaccines, which we believe has delivered promising phase I efficacy data in malignant melanoma. We view the current share price as an attractive entry opportunity for long-term-oriented investors.

Länk till analysen i sin helhet: https://www.redeye.se/research/837644/ultimovacs-a-universal-cancer-vaccine?utm_source=finwire&utm_medium=RSS